X-ray contrast firm E-Z-EM hopes to develop new imaging agentsbased on microsphere technology it has licensed from InteractiveMedical Technologies. E-Z-EM, of Westbury, NY, has an option onan exclusive license for all applications of the technology,
X-ray contrast firm E-Z-EM hopes to develop new imaging agentsbased on microsphere technology it has licensed from InteractiveMedical Technologies. E-Z-EM, of Westbury, NY, has an option onan exclusive license for all applications of the technology, includingultrasound detection of pulmonary embolism and myocardial ischemia.The agreement also includes global sales and marketing of productsbased on the technology.
Interactive Medical Technologies has developed albumin-basedmicrospheres, which can be manufactured in sizes as small as onemicron. Under the terms of the agreement, E-Z-EM will begin preclinicalsafety testing of the microspheres at Dartmouth Medical Schoolin Hanover, NH, and the company will also analyze the regulatorycosts for conducting additional clinical trials.
"E-Z-EM is especially interested in this unique technologyas it could relate to various imaging applications in our targetmarkets," said E-Z-EM president and CEO Daniel Martin. "Contrastmicrospheres could have applications in enhancing the measurementof blood flow by ultrasound."
In other E-Z-EM news, the company in February introduced anew barium sulfate contrast agent for CT exams of the abdomenand pelvis. The new product will be marketed as E-Z-CAT Dry.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.